SynthesisScientific reports2018
Relative Efficacy of Checkpoint Inhibitors for Advanced NSCLC According to Programmed Death-Ligand-1 Expression: A Systematic Review and Network Meta-Analysis.
Synthesis in Scientific reports, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 3 syntheses or guidelines pooled it.
- Anti-TIGIT therapies for solid tumors: a systematic review.ESMO open · 2023Pooled it
- Targeted therapy for advanced anaplastic lymphoma kinase (<I>ALK</I>)-rearranged non-small cell lung cancer.The Cochrane database of systematic reviews · 2022Pooled it
- Response Rate and Survival at Key Timepoints With PD-1 Blockade vs Chemotherapy in PD-L1 Subgroups: Meta-Analysis of Metastatic NSCLC Trials.JNCI cancer spectrum · 2021Pooled it
- Multidimensional analysis of tumour immune microenvironment in HCC: prognostic significance and implications for immunotherapy.Cancer immunology, immunotherapy : CII · 2026Article
- Article
- Clinical predictors of response to single‑agent immune checkpoint inhibitors in chemotherapy‑pretreated non‑small cell lung cancer.Molecular and clinical oncology · 2024Article
- Effectiveness of first-line anticancer treatment may predict treatment response in further lines in stage III/IV patients with non-small cell lung cancer.Journal of cancer research and clinical oncology · 2023Article
- Bayesian hierarchical model-based network meta-analysis to overcome survival extrapolation challenges caused by data immaturity.Journal of comparative effectiveness research · 2023Article
- Paclitaxel-bevacizumab combination in advanced non-squamous non-small-cell lung cancer (NSCLC): AVATAX, a retrospective multicentric study.Therapeutic advances in medical oncology · 2022Article
- Effects of programmed death ligand 1 on the prognosis of neuroblastoma: A protocol for systematic review and meta analysis.Medicine · 2021Article
- PD-L1 expression in regional lymph nodes and predictable roles in anti-cancer immune responses.Journal of clinical and experimental hematopathology : JCEH · 2020Article
- Compare the efficacy and safety of programmed cell death-1 (PD-1) and programmed cell death ligand-1 (PD-L1) inhibitors for advanced non-small cell lung cancer: a Bayesian analysis.Translational lung cancer research · 2020Article
- Review
- Second-line treatment strategy for urothelial cancer patients who progress or are unfit for cisplatin therapy: a network meta-analysis.BMC urology · 2019Article
- An Exceptional Responder to Nivolumab in Metastatic Non-Small-Cell Lung Cancer: A Case Report and Literature Review of Long-Term Survivors.Case reports in oncological medicine · 2019Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Although currently available immune checkpoint inhibitors with similar but slightly different indications are recommended for patients with advanced non-small cell lung cancer (NSCLC), their effects by programmed death-ligand-1 (PD-L1) expression level are not yet known. This meta-analysis aims to assess the survival benefit and comparative efficacy of checkpoint inhibitors according to PD-L1 expression level: <1%, 1-49%, and ≥50%. We searched the MEDLINE, EMBASE, and Cochrane database through December 2017. A fixed-effect Bayesian network meta-analysis (NMA) was performed to estimate hazard ratios (HRs) for overall survival (OS) with 95% credible intervals (CrIs). Seven trials including 3688 patients were selected from among the 673 screened studies. Checkpoint inhibitor remarkably improved OS over chemotherapy in the PD-L1 ≥ 50% subgroup compared with the PD-L1 < 1% and PD-L1 1-49% subgroups. Atezolizumab, nivolumab, and nivolumab were the most effective agents for second- or later-line settings in the PD-L1 < 1%, PD-L1 1-49%, and PD-L1 ≥ 50% subgroups, respectively. PD-L1 expression ≥50% on tumor cells could be a reliable indicator that helps patient selection in view of cost-efficiency, and each checkpoint inhibitor reported to be the best agent by PD-L1 expression level could be carefully recommended in each PD-L1 expression subgroup.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.